Company Overview

OXiGENE, Inc. develops novel therapeutics to treat cancer and eye diseases in the United States. It primarily focuses on the development of vascular disrupting agents (VDAs) that disable and destroy abnormal blood vessels, which provide solid tumors a means of growth and survival, as well as associate with visual impairment in various ophthalmological diseases and conditions. The company?s products include ZYBRESTAT, which is in fosbretabulin in anaplastic cancer of the thyroid (FACT) trial?Phase 2/3 study for the treatment of anaplastic thyroid cancer; in fosbretabulin in advanced lung oncology (FALCON) trial?Phase 2 randomized and controlled study to treat non-small cell lung cancer;...

read more


To see the headquarters in Google Street View &trade, drag this yellow guy: over to the red pointer:

Contact Information:

Business Address: 701 Gateway Boulevard, Suite 210, South San Francisco, CA 94080, United States
Mailing Address: -
Phone: 650-635-7000
Fax: 650-635-7001
Website: http//www.oxigene.com

Company Details:

Symbol: OXGN
SIC: 2836
State location: CA
Sector: -
State of Inc: DE
Employees: 22
Type: -

Key executives:

Name Age Position
David Chaplin Ph.D. 65 Exec. Vice Chairman, Chief Scientific Officer and Head of R&D
James B. Murphy 64 Chief Financial Officer and VP
Peter A. Harris 2021 Chief Medical Officer
Richard Chin M.D. 54 Chief Exec. Officer, Pres
Susan Hager 2021 Director of Communications